Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 in Multiple Solid Tumors Including Urinary System Tumors
NCT05785039Phase 2Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Apr 2023
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of izalontamab brengitecan in urinary system tumor and solid tumor, sponsored by Biokin Pharmaceutical. Primary endpoints: Recommended Phase II Dose at 24 months and Objective Response Rate at 24 months. Started Apr 2023; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
urinary system tumorsolid tumor
Beyond the preview
Go deeper on NCT05785039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05785039.